Momentum Building: Delcath Systems Spikes on HEPZATO KIT's FDA Nod
- August 15th, 2023
- 324 views
Shares of Delcath Systems, Inc. (Nasdaq: DCTH) surged over 50% following the announcement of FDA approval for HEPZATO KIT (melphalan/Hepatic Delivery System).
This liver-directed therapy is now authorized for adult patients battling metastatic uveal melanoma (mUM), specifically those with unresectable hepatic metastases affecting less than 50% of the liver and limited extrahepatic disease.
This approval addresses a rare and aggressive cancer with high liver involvement, making it a significant advancement in treatment options and the company plans to make the commercial product available in the fourth quarter.
$DCTH was trading at $5.35 in pre-market, reflecting a substantial increase of $2.23 (+71.47%)
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
NJCP National Football Conference Names David Dalton Head Coach of Salt Lake Yeti
February 06th, 2026FDA Takes New Approach to "No Artificial Colors" Claims
February 06th, 2026NJCP National Football Conference Announces Micah Deckart as Head Coach of the Idaho Outlaws
February 05th, 2026
Member Login